Erlotinib | Khurana And Khurana Advocates and IP Attorneys

Roche v Cipla: Part 2: Infringement

14th November, 2012 - 5:11 am Categories: IP Practice in India Pharma/Biotech Patent Litigations

In continuation of the last piece over here, let’s now discuss the actual issue of infringement of IN ‘774 patent by Cipla crisply. My apologies for a long delay in writing this piece due to long travelling schedule and back-to-back heavy projects thereafter. Nevertheless, it is better to be late than never. Here it goes. … Continue reading Roche v Cipla: Part 2: Infringement

Roche v Cipla: Part 1: Validity of Patent

26th September, 2012 - 7:53 am Categories: IP Litigation IP Practice in India News & Updates Pharma/Biotech Patent Litigations

0 Comments

In continuation of our previous post here, and following the availability of the 275 page judgement, we would discuss herein the various facets of the case and discuss one by one. This case actually involved two main issues as follows, Issue I. Whether Roche’s Indian Patent 196774 is invalid (liable to be revoked under S. … Continue reading Roche v Cipla: Part 1: Validity of Patent

Cipla won the landmark Roche v Cipla Litigation

8th September, 2012 - 10:46 am Categories: IP Practice in India News & Updates Pharma/Biotech Patent Litigations

0 Comments

Indian Generic manufacturer Cipla has won the landmark Roche v. Cipla Patent Infringement case in the Delhi High Court over Cipla’s Generic version of Anti-cancer Drug Erlotinib. The case is the first Patent Litigation in India post India’s 2005 Product Patent Regime which included public interest and pricing issues in addition to India’s Section 3d … Continue reading Cipla won the landmark Roche v Cipla Litigation

Tag: Erlotinib

Roche v Cipla: Part 2: Infringement

Roche v Cipla: Part 1: Validity of Patent

Cipla won the landmark Roche v Cipla Litigation

Categories

Archives